4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) had its price target cut by Leerink Partners from $31.00 to $27.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners’ price objective points to a potential upside of 453.28% from the company’s previous close.
Other analysts also recently issued research reports about the company. Bank of America lowered their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $40.00 to $15.00 in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday. Royal Bank of Canada decreased their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $39.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $38.56.
Check Out Our Latest Report on FDMT
4D Molecular Therapeutics Trading Up 2.5 %
Institutional Trading of 4D Molecular Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of FDMT. Rhumbline Advisers raised its holdings in 4D Molecular Therapeutics by 14.2% in the 2nd quarter. Rhumbline Advisers now owns 72,933 shares of the company’s stock valued at $1,531,000 after acquiring an additional 9,062 shares during the period. Quest Partners LLC increased its stake in shares of 4D Molecular Therapeutics by 17,409.1% during the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after purchasing an additional 5,745 shares during the period. American Century Companies Inc. acquired a new stake in 4D Molecular Therapeutics during the 2nd quarter worth approximately $268,000. Parallel Advisors LLC boosted its stake in 4D Molecular Therapeutics by 59,833.3% in the 2nd quarter. Parallel Advisors LLC now owns 19,778 shares of the company’s stock valued at $415,000 after purchasing an additional 19,745 shares during the period. Finally, Sofinnova Investments Inc. grew its holdings in 4D Molecular Therapeutics by 36.8% in the 2nd quarter. Sofinnova Investments Inc. now owns 271,155 shares of the company’s stock valued at $5,692,000 after buying an additional 72,969 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Read More
- Five stocks we like better than 4D Molecular Therapeutics
- Consumer Discretionary Stocks Explained
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What Are Dividend Challengers?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.